Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 10/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 6/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 5/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 2/20 | 0.32 |
| ▸ | HTR1D | P28221 | 2/20 | 0.32 |
| ▸ | DRD3 | P35462 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16872206 | 0.97 | BCHE (0.34) | SMN1; SMN2L3MBTL1ACHEKDM4EBCHE | |
| SCHEMBL18584373 | 0.81 | SMN1; SMN2 (0.35) | SMN1; SMN2L3MBTL1KDM4EDRD2DRD3 | |
| SCHEMBL18584455 | 0.80 | KDM4E (0.39) | SMN1; SMN2L3MBTL1ACHEKDM4EBCHE | |
| SCHEMBL18584378 | 0.78 | SMN1; SMN2 (0.36) | SMN1; SMN2L3MBTL1ACHEKDM4EDRD2 | |
| SCHEMBL18584379 | 0.78 | KDM4E (0.33) | SMN1; SMN2L3MBTL1ACHEKDM4EBCHE | |
| SCHEMBL16872097 | 0.78 | ACHE (0.38) | SMN1; SMN2L3MBTL1ACHEKDM4EBCHE | |
| SCHEMBL18584588 | 0.77 | KDM4E (0.42) | SMN1; SMN2L3MBTL1ACHEKDM4EMAPT | |
| SCHEMBL18584530 | 0.75 | ACHE (0.43) | ACHEKDM4EBCHE | |
| SCHEMBL16739336 | 0.73 | POLB (0.58) | SMN1; SMN2L3MBTL1ACHEBCHEGRIN1 | |
| SCHEMBL25249951 | 0.72 | SMN1; SMN2 (0.40) | SMN1; SMN2L3MBTL1ACHEKDM4EBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150225404-A1 | PYRIDINE DERIVATIVE AND MEDICINE | NIPPON SHINYAKU CO., LTD. (JP) | 2015-08-13 | — | — | US | disclosed |
| EP-2891656-A1 | PYRIDINE DERIVATIVE AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2015-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225404-A1 | PYRIDINE DERIVATIVE AND MEDICINE | TRPV1, TRPV5, TRPM5 | SMN1; SMN2 1815/4885L3MBTL1 4075/4885ACHE 1178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.